The effects of granulocyte-colony stimulating factor in bare stent and sirolimus-eluting stent in pigs following myocardial infarction

Lim, Sang Yup; Kim, Yong Sook; Ahn, Youngkeun; Rok, Lee Sang; Kim, Ju Han; Kim, Key Hun; Park, Hyung Wook; Kim, Weon; Cho, Jeong Gwan; Park, Jong Chun; Kang, Peter M.; Schwartz, Robert S.; Kang, Jung Chaee

doi:10.1016/j.ijcard.2006.07.018

Cited by 7 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that G-CSF could activate and induce the proliferation of vascular smooth muscle cells in injured arteries [76,77]. Increased neointimal formation and in-stent restenosis in coronaries treated with bare, but drug-eluting stents were observed in G-CSF-treated pigs submitted to myocardial infarction [78]. This may help to explain the increased in-stent restenosis in subjects observed in the MAGIC Study [49], who received G-CSF treatment and PCIs with bare stents.…”

Section: Clinical Studiesmentioning

confidence: 95%

Granulocyte colony-stimulating factor for ischemic heart failure: should we use it?

2010

View full text Add to dashboard Cite

Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic cytokine usually used in the treatment of patients with cancer. Studies have shown regenerative properties of bone marrow stem cell mobilization due to G-CSF in animals. Moreover, others effects related to G-CSF and independent of tissue regeneration were shown to be protective. As a result, this cytokine has been tested as a therapy for ischemic heart failure in humans. However, when this treatment was evaluated in clinical trials, the beneficial effects seen in small animals were not confirmed in infarcted patients. Thus, we sought to review the effects of G-CSF after an ischemic insult and on the progression of heart failure in animals and humans.

show abstract

Section: Clinical Studiesmentioning

confidence: 95%

Granulocyte colony-stimulating factor for ischemic heart failure: should we use it?

2010

View full text Add to dashboard Cite

show abstract

“…Nonetheless, G-CSF administration itself has been shown to be associated with enhanced neointimal hyperplasia, possibly by the stimulation of excessive proliferation and the migration of smooth muscle cells, thus promoting re-stenosis of stented arteries [61]. Moreover, the possibility remains that EPCs may be independently responsible for stent restenosis, as a strong correlation has been shown between circulating CD34 + cells and late luminal loss following coronary angiography [62].…”

Section: Introductionmentioning

confidence: 99%

Endothelial progenitor cells: what use for the cardiologist?

et al. 2010

View full text Add to dashboard Cite

Endothelial Progenitor Cells (EPC) were first described in 1997 and have since been the subject of numerous investigative studies exploring the potential of these cells in the process of cardiovascular damage and repair. Whilst their exact definition and mechanism of action remains unclear, they are directly influenced by different cardiovascular risk factors and have a definite role to play in defining cardiovascular risk. Furthermore, EPCs may have important therapeutic implications and further understanding of their pathophysiology has enabled us to explore new possibilities in the management of cardiovascular disease. This review article aims to provide an overview of the vast literature on EPCs in relation to clinical cardiology.

show abstract

“…Furthermore, intramyocardial VEGF gene transfer followed by bone marrow stem cell mobilization using G-CSF was safe however did not significantly improve myocardial perfusion as assessed by single photon emission computerized tomography (66). G-CSF aggravated in-stent re-stensosis, which was partly dependent on VEGF and STAT-3, although this may be reduced by using a sirolimus drug-eluting stent (67).…”

Section: Discussionmentioning

confidence: 99%

Effects of granulocyte colony‑stimulating factor on rabbit carotid and porcine heart models of chronic obliterative arterial disease

Chen

Wang

et al. 2019

Mol Med Report

View full text Add to dashboard Cite

Previous studies suggest that granulocyte colony-stimulating factor (G-cSF) can promote bone marrow derived progenitor cells to mediate cardiovascular repair, potentially reversing mechanical dysfunction in chronic ischaemic heart disease and post myocardial infarction. Two models were used in the present study both using a surgical ameroid constrictor to induce arterial stenosis. The first model used the carotid artery of rabbits. They were divided into high fat diet (inducing atherosclerosis) or normal fat diet (control) groups. each was subdivided into surgical exposure group without constrictor, ameroid constrictor receiving normal saline or receiving G-cSF 15 µg/kg/day. endothelial markers of endothelial nitric oxide synthase and endothelin 1 were increased by the use of ameroid constrictor in both atherosclerotic and non-atherosclerotic mice, however were not further altered by G-cSF. Scanning electron microscopy indicated that ameroid constrictor application altered endothelial morphology from an oval shape to a round shape and this was more prominent in the atherosclerotic compared with the non-atherosclerotic group. G-cSF injection increased the number of endothelial cells in all groups. The second model used the left coronary artery of pigs. They were equally divided into following groups, receiving normal saline (control), G-cSF 2.5 µg/kg/day (low dose), 5 µg/kg/day (medium dose) and 10 µg/kg/day (high dose) for 5 days. G-cSF at a low or high dose worsened intimal hyperplasia however at a medium dose improved it. in conclusion, G-cSF had no effect in a rabbit carotid artery model of atherosclerosis. its effects on the porcine heart were dose-dependent; arterial disease worsened at a low or high dose, but improved at a medium dose.

show abstract

The effects of granulocyte-colony stimulating factor in bare stent and sirolimus-eluting stent in pigs following myocardial infarction

Cited by 7 publications

References 35 publications

Granulocyte colony-stimulating factor for ischemic heart failure: should we use it?

Granulocyte colony-stimulating factor for ischemic heart failure: should we use it?

Endothelial progenitor cells: what use for the cardiologist?

Effects of granulocyte colony‑stimulating factor on rabbit carotid and porcine heart models of chronic obliterative arterial disease

Contact Info

Product

Resources

About